Status:
COMPLETED
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Lead Sponsor:
Cipherome, Inc.
Collaborating Sponsors:
DHR Health Institute for Research and Development
Conditions:
Thrombosis
Stent Thrombosis
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or asse...
Detailed Description
The Lighthouse tool incorporates pharmacogenetic (PGx) variants from well-established, evidence-based guidelines to provide personalized drug response profile(s) to guide treatment decisions. The pat...
Eligibility Criteria
Inclusion
- Subjects over 18 years of age, who are:
- On clopidogrel, prasugrel or ticagrelor after percutaneous stent
- Completed informed consent
Exclusion
- Failure to provide informed consent.
- Lost to follow-up prior to 60 days.
Key Trial Info
Start Date :
December 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 27 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04702113
Start Date
December 3 2020
End Date
July 27 2023
Last Update
September 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Doctors Hospital at Renaissance
Edinburg, Texas, United States, 78539